DATE

Initial Approval: April 12, 2017

## **CRITERIA FOR PRIOR AUTHORIZATION**

Rubraca™ (rucaparib)

PROVIDER GROUP Pharmacy

**MANUAL GUIDELINES** The following drugs requires prior authorization:

Rucaparib (Rubraca™)

**CRITERIA FOR APPROVAL** (Must meet the following criteria):

- Patient must have a diagnosis of advanced ovarian cancer
- Patient must have a deleterious BRCA mutation (germline and/or somatic)
- Patient must have been treated with two or more chemotherapies
- Must be used as monotherapy
- Patient must be 18 years of age or older
- · Patient must not be pregnant or breastfeeding

**LENGTH OF APPROVAL** 12 months

\*Information on the FDA-approved test for the detection of a tumor BRCA mutation in patients with ovarian cancer is available at: <a href="http://www.fda.gov/CompanionDiagnostics">http://www.fda.gov/CompanionDiagnostics</a>.

DRUG UTILIZATION REVIEW COMMITTEE CHAIR

PHARMACY PROGRAM MANAGER

DIVISION OF HEALTH CARE FINANCE

KANSAS DEPARTMENT OF HEALTH AND ENVIRONMENT

DATE